Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16.

PMID:
18417744
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M; Epoetin Alfa Extended Dosing Study Group.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1015-21. doi: 10.2215/CJN.05681207. Epub 2008 Apr 9.

PMID:
18400964
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.

Bradbury BD, Danese MD, Gleeson M, Critchlow CW.

Clin J Am Soc Nephrol. 2009 Mar;4(3):630-7. doi: 10.2215/CJN.03580708. Epub 2009 Mar 4.

PMID:
19261826
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17.

PMID:
19808215
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM.

Am J Nephrol. 2013;37(6):549-58. doi: 10.1159/000351175. Epub 2013 May 25.

PMID:
23735819
[PubMed - indexed for MEDLINE]
6.

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.

Foley RN, Curtis BM, Parfrey PS.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1669-75. doi: 10.2215/CJN.02100508. Epub 2008 Oct 15.

PMID:
18922988
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1006-14. doi: 10.2215/CJN.05671207. Epub 2008 Apr 16.

PMID:
18417741
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.

PMID:
22752396
[PubMed - indexed for MEDLINE]
9.

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.

Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.

Crit Care Med. 2006 Jun;34(6):1661-7.

PMID:
16607233
[PubMed - indexed for MEDLINE]
10.

Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease.

Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L.

Clin J Am Soc Nephrol. 2009 Mar;4(3):552-9. doi: 10.2215/CJN.04380808. Epub 2009 Mar 4.

PMID:
19261821
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P.

Clin J Am Soc Nephrol. 2010 Apr;5(4):598-606. doi: 10.2215/CJN.06770909. Epub 2010 Feb 25.

PMID:
20185602
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group.

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
[PubMed - indexed for MEDLINE]
13.

Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.

Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.

J Manag Care Pharm. 2009 Nov-Dec;15(9):741-50.

PMID:
19954265
[PubMed - indexed for MEDLINE]
Free Article
14.

An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.

Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.

J Am Med Dir Assoc. 2012 Mar;13(3):244-8. doi: 10.1016/j.jamda.2010.09.009. Epub 2010 Nov 11.

PMID:
21450214
[PubMed - indexed for MEDLINE]
15.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

PMID:
17699476
[PubMed - indexed for MEDLINE]
Free Article
16.

Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?

Pussell BA, Walker R; Australian Renal Anaemia Group.

Nephrology (Carlton). 2007 Apr;12(2):126-9.

PMID:
17371333
[PubMed - indexed for MEDLINE]
17.

The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.

Coyne DW.

Kidney Int. 2012 Jul;82(2):235-41. doi: 10.1038/ki.2012.76. Epub 2012 Mar 21.

PMID:
22437411
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.

McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr; End-Stage Renal Disease Core Indicators Work Group.

Am J Kidney Dis. 2001 May;37(5):E36.

PMID:
11325701
[PubMed - indexed for MEDLINE]
19.

Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?

Walker RG.

Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25. No abstract available.

PMID:
18579671
[PubMed - indexed for MEDLINE]
Free Article
20.

Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.

Abe M, Okada K, Soma M, Matsumoto K.

Clin Nephrol. 2011 Jan;75(1):49-58.

PMID:
21176750
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk